Cream - 10 mg / 1 g

Tablets - 15 mg

Syrup - (0.6 mg + 0.08 mg + 40 mg + 90 mg ) / 1 g

Syrup - (0.6 mg + 0.08 mg + 40 mg + 90 mg ) / 1 g

Solution for injection - 100 mcg/ml

Solution for injection - 500 mcg/ml

Film coated tablets - 500 mg

Tablets - 0.5 mg

Tablets - 0.5 mg

Solution for injection - 4 mg/ml

Cream – (0.15% + 0.5%) – 15 g

Dexa-Neo is a pharmaceutical product that contains the active substances dexamethasone sodium phosphate and neomycin sulphate. Dexamethasone sodium phosphate is a synthetic glucocorticoid, analogue of natural glucocorticoids, with strong anti-inflammatory and anti-allergic activity. Neomycin sulphate is a broad-spectrum antibiotic, with a bactericidal activity against Gram-negative and Gram-positive microorganisms.

Dexa-Neo is used:

• as a short-term treatment in inflammatory skin diseases that respond to steroids, where is also required a prophylactic treatment with antibiotics, only after the exclusion of the viral and fungal diseases; it has also a local action as anti-pruritic and vasoconstrictor although the mechanism of action of the corticosteroids is not yet very clear;
• for the treatment of skin diseases, when there isasecondaryinfection like eczema,psoriasis, dermatitis, neurodermatitis, contactsensitivityreactions;

for the treatment of secondary infections by insect bites as well as for the treatment of anogenital pruritus.

Eye Ointment - (0.5 mg + 5 mg)/g - 3.5 g

Eye ointment – (0.05% + 0.5%) – 3.5 g

Syrup - 15 mg / 5 ml

Rectal solution - 5 mg/2.5 ml

Tablets - 5 mg

Solution for injection - (0.5%) 10 mg/2 ml

Suppositories - 100 mg

Durilac contains the active substance diclofenac sodium, which is a non-steroidal anti-inflammatory drug (NSAID). Its action is based in the inhibition of cyclooxygenases, which participate in the biosynthesis of prostaglandins. Prostaglandins have an important role in the process of pain, inflammation and chills. Non - steroidal anti-inflammatory drugs inhibit cyclooxygenases-1 and-2 (COX-1 and-2). Inhibition of COX-1 is associated with gastrointestinal side effects, while the inhibition of COX-2 is associated with anti-inflammatory action.

Diclofenac is rapidly absorbed when it is given in the form of rectal suppositories or intramuscular injection. Diclofenac is also absorbed percutaneously. Approximately 99 % of the drug is bound with the plasma proteins. Diclofenac passes in the synovial fluid and in the breast milk. Its plasmatic half life is 1 – 2 hours. It is excreted in the form of glucuronides and sulphates, mainly through urine (65 %) and bile (35 %).

Durilac is used:

• in musculo-skeletal disorders such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis;
• in peri-articular disorders such as bursitis and tendinitis;
• in soft-tissue disorders such as sprains and strains;
• in painful conditions such as renal colic, acute gout, dysmenorrhoea;
• after some surgical procedures.

Solution for injection - 75 mg / 3 ml

Durilac contains the active substance diclofenac sodium, which is a non-steroidal anti-inflammatory drug (NSAID). Its action is based in the inhibition of cyclooxygenases, which participate in the biosynthesis of prostaglandins. Prostaglandins have an important role in the process of pain, inflammation and chills. Non - steroidal anti-inflammatory drugs inhibit cyclooxygenases-1 and-2 (COX-1 and-2). Inhibition of COX-1 is associated with gastrointestinal side effects, while the inhibition of COX-2 is associated with anti-inflammatory action.

Diclofenac is rapidly absorbed when it is given in the form of rectal suppositories or intramuscular injection. Diclofenac is also absorbed percutaneously. Approximately 99 % of the drug is bound with the plasma proteins. Diclofenac passes in the synovial fluid and in the breast milk. Its plasmatic half life is 1 – 2 hours. It is excreted in the form of glucuronides and sulphates, mainly through urine (65 %) and bile (35 %).

Durilac is used:

• in musculo-skeletal disorders such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis;
• in peri-articular disorders such as bursitis and tendinitis;
• in soft-tissue disorders such as sprains and strains;
• in painful conditions such as renal colic, acute gout, dysmenorrhoea;
• after some surgical procedures.

Gel - 1%

Durilac contains the active substance diclofenac sodium, which is a non-steroidal anti-inflammatory drug (NSAID). Its action is based in the inhibition of cyclooxygenases, which participate in the biosynthesis of prostaglandins. Prostaglandins have an important role in the process of pain, inflammation and chills. Non - steroidal anti-inflammatory drugs inhibit cyclooxygenases-1 and-2 (COX-1 and-2). Inhibition of COX-1 is associated with gastrointestinal side effects, while the inhibition of COX-2 is associated with anti-inflammatory action.

Diclofenac is rapidly absorbed when it is given in the form of rectal suppositories or intramuscular injection. Diclofenac is also absorbed percutaneously. Approximately 99 % of the drug is bound with the plasma proteins. Diclofenac passes in the synovial fluid and in the breast milk. Its plasmatic half life is 1 – 2 hours. It is excreted in the form of glucuronides and sulphates, mainly through urine (65 %) and bile (35 %).

Durilac is used:

• in musculo-skeletal disorders such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis;
• in peri-articular disorders such as bursitis and tendinitis;
• in soft-tissue disorders such as sprains and strains;
• in painful conditions such as renal colic, acute gout, dysmenorrhoea;
• after some surgical procedures.